{"title_page": "Camrelizumab", "text_new": "{{Infobox drug\n| type              = mab\n| image             = \n| alt               = \n| mab_type          = mab\n| source            = zu\n| target            = [[programmed cell death 1|PD1]]\n| pronounce         =\n| tradename         = \n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = \n| pregnancy_US      = \n| pregnancy_category=  \n| legal_AU = \n| legal_AU_comment =\n| legal_BR =  \n| legal_BR_comment =\n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_UN = \n| legal_NZ = \n| legal_status      = \n| routes_of_administration = \n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| metabolites       =\n| onset             = \n| elimination_half-life = \n| duration_of_action=\n| excretion         =\n| CAS_number        = 1798286-48-2\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 73096E137E\n| ATC_prefix        = none\n| ATC_suffix        = \n| PubChem           = \n| DrugBank          = \n| C = | H = | N = | O = | S = \n| molecular_weight  = \n| synonyms = SHR-1210\n}}\n\n'''Camrelizumab''' ('''SHR-1210''') ([[International Nonproprietary Name|INN]]<ref name=WHOList117>{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77 | journal = WHO Drug Information | volume = 31 | issue = 1 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL77.pdf | author-link = World Health Organization }}</ref>) is an anti-PD-1 immune [[checkpoint inhibitor]] that is being investigated for [[hepatocellular carcinoma]] and [[Hodgkin lymphoma]]<ref>{{Cite journal |doi = 10.1200/JCO.18.02151|title = Addition of Low-Dose Decitabine to Anti\u2013PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma|journal = Journal of Clinical Oncology|volume = 37|issue = 17|pages = 1479\u20131489|year = 2019|last1 = Nie|first1 = Jing|last2 = Wang|first2 = Chunmeng|last3 = Liu|first3 = Yang|last4 = Yang|first4 = Qingming|last5 = Mei|first5 = Qian|last6 = Dong|first6 = Liang|last7 = Li|first7 = Xiang|last8 = Liu|first8 = Jiejie|last9 = Ku|first9 = Wenjing|last10 = Zhang|first10 = Yan|last11 = Chen|first11 = Meixia|last12 = An|first12 = Xiaojing|last13 = Shi|first13 = Lu|last14 = Brock|first14 = Malcolm V.|last15 = Bai|first15 = Jie|last16 = Han|first16 = Weidong}}</ref>.\n\nThis drug is being developed by Jiangsu HengRui Medicine Co., Ltd. {{as of|2019}}, camrelizumab is undergoing [[Phases of clinical research#Phase_II|Phase II]]/[[Phase III|III]] trials.\n\n== References ==\n<references/>\n{{monoclonal-antibody-stub}}\n{{monoclonals for immune system}}\n[[Category:Monoclonal antibodies]]\n", "text_old": "{{Infobox drug\n| type              = mab\n| image             = \n| alt               = \n| mab_type          = mab\n| source            = zu\n| target            = [[programmed cell death 1|PD1]]\n| pronounce         =\n| tradename         = \n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = \n| pregnancy_US      = \n| pregnancy_category=  \n| legal_AU = \n| legal_AU_comment =\n| legal_BR =  \n| legal_BR_comment =\n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_UN = \n| legal_NZ = \n| legal_status      = \n| routes_of_administration = \n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| metabolites       =\n| onset             = \n| elimination_half-life = \n| duration_of_action=\n| excretion         =\n| CAS_number        = 1798286-48-2\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 73096E137E\n| ATC_prefix        = none\n| ATC_suffix        = \n| PubChem           = \n| DrugBank          = \n| C = | H = | N = | O = | S = \n| molecular_weight  = \n| UNII = \n| synonyms = SHR-1210\n}}\n\n'''Camrelizumab''' ('''SHR-1210''') ([[International Nonproprietary Name|INN]]<ref name=WHOList117>{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77 | journal = WHO Drug Information | volume = 31 | issue = 1 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL77.pdf | author-link = World Health Organization }}</ref>) is an anti-PD-1 immune [[checkpoint inhibitor]] that is being investigated for [[hepatocellular carcinoma]] and [[Hodgkin lymphoma]]<ref>{{Cite journal |doi = 10.1200/JCO.18.02151|title = Addition of Low-Dose Decitabine to Anti\u2013PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma|journal = Journal of Clinical Oncology|volume = 37|issue = 17|pages = 1479\u20131489|year = 2019|last1 = Nie|first1 = Jing|last2 = Wang|first2 = Chunmeng|last3 = Liu|first3 = Yang|last4 = Yang|first4 = Qingming|last5 = Mei|first5 = Qian|last6 = Dong|first6 = Liang|last7 = Li|first7 = Xiang|last8 = Liu|first8 = Jiejie|last9 = Ku|first9 = Wenjing|last10 = Zhang|first10 = Yan|last11 = Chen|first11 = Meixia|last12 = An|first12 = Xiaojing|last13 = Shi|first13 = Lu|last14 = Brock|first14 = Malcolm V.|last15 = Bai|first15 = Jie|last16 = Han|first16 = Weidong}}</ref>.\n\nThis drug is being developed by Jiangsu HengRui Medicine Co., Ltd. {{as of|2019}}, camrelizumab is undergoing [[Phases of clinical research#Phase_II|Phase II]]/[[Phase III|III]] trials.\n\n== References ==\n<references/>\n{{monoclonal-antibody-stub}}\n{{monoclonals for immune system}}\n[[Category:Monoclonal antibodies]]\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Camrelizumab"}
